The patient's oncologist must determine that expanded access is appropriate and contact the drug manufacturer to request the investigational drug. The manufacturer must agree to provide the drug for the patient. The oncologist must then submit an application to the U.S. Food and Drug Administration (FDA) or the corresponding regulatory authority in other countries. Upon FDA approval, an Institutional Review Board (IRB) must review and approve the treatment protocol.
